FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"
Executive Summary
Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.
You may also be interested in...
PDUFA Reaches Approval Altitude; Can House Maintain Senate Speed?
After about a week of debate, the Senate overwhelmingly passes its FDA user fee package, with only track and trace to be finalized. House members are scheduled to begin floor debate after Memorial Day in the hopes of sending the bill to President Obama before July 4.
User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop
Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.
CMS 2012 Budget Looks To Biosimilars, Brand/Generic Deals To Offset Costs
In its 2012 budget proposal for the Centers for Medicare and Medicaid Services, the Obama administration casts its net wide to find potential savings from prescription drug spending to help offset Medicare and Medicaid costs.